secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001104659-26-038882
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch
--------------------------------------------------------------------------------

- Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.
- Net proceeds expected ~$282M after underwriting discounts and expenses; closing on or about April 6, 2026.
- Underwriters granted 30-day option to purchase up to an additional 1,551,750 shares (15%).
- Proceeds to fund commercial readiness and launch of barzolvolimab for CSU (if approved), clinical/preclinical development, and bispecific platform.
- Lead managers include Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465926038882/0001104659-26-038882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465926038882/tm267111d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-038882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer